Aging, immune senescence, and immunotherapy: A comprehensive review
The advent of immune checkpoint inhibitors (ICIs) has changed the landscape of cancer treatment. Older adults represent the majority of cancer patients; however, direct data evaluating ICIs in this patient population is lacking. Aging is associated with changes in the immune system known as “immunos...
Gespeichert in:
| Veröffentlicht in: | Seminars in oncology 2018-08, Vol.45 (4), p.187-200 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 200 |
|---|---|
| container_issue | 4 |
| container_start_page | 187 |
| container_title | Seminars in oncology |
| container_volume | 45 |
| creator | Elias, Rawad Hartshorn, Kevan Rahma, Osama Lin, Nina Snyder-Cappione, Jennifer E. |
| description | The advent of immune checkpoint inhibitors (ICIs) has changed the landscape of cancer treatment. Older adults represent the majority of cancer patients; however, direct data evaluating ICIs in this patient population is lacking. Aging is associated with changes in the immune system known as “immunosenescence” that could impact the efficacy and safety profile of ICIs. In this paper, we review aging-associated changes in the immune system as they may relate to cancer and immunotherapy, with mention of the effect of chronic viral infections and frailty. Furthermore, we summarize the current clinical evidence of ICI effectiveness and toxicity among older adults with cancer. |
| doi_str_mv | 10.1053/j.seminoncol.2018.08.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2155160655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093775418300034</els_id><sourcerecordid>2155160655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-baf66e5c384bd65685718be04ca9d6b4b5f555a0e286d494cd567bfb94b8802c3</originalsourceid><addsrcrecordid>eNqFkM9OwzAMxiMEgjF4BdQjBzqcNklTbmPinzSJC5yjJnVHpjUdyTa0G2_EO_EkZGzAEcmSJfuzP_tHSEJhQIHnl9NBwNa6zpluNsiAygHEALFHepTnWSoLkPukB1DmaVFwdkSOQ5gCZLTIskNylMclZUFZjzwMJ9ZNLj7fP2zbLh0mAR0Gg87gpli5OvludIsX9NV8fRWLw8R07dzjC7pgV5h4XFl8OyEHTTULeLrLffJ8e_M0uk_Hj3cPo-E4NXnBFqmuGiGQm1wyXQsuJC-o1AjMVGUtNNO84ZxXgJkUNSuZqbkodKNLpqWEzOR9cr7dO_fd6xLDQrU2HjybVQ67ZVAZ5ZwKEJxHqdxKje9C8Nioubdt5deKgtqAVFP1B1JtQCqIASKOnu1clrrF-nfwh1wUXG8FGH-N_3sVjN1gq61Hs1B1Z_93-QKXBo2a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2155160655</pqid></control><display><type>article</type><title>Aging, immune senescence, and immunotherapy: A comprehensive review</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Elias, Rawad ; Hartshorn, Kevan ; Rahma, Osama ; Lin, Nina ; Snyder-Cappione, Jennifer E.</creator><creatorcontrib>Elias, Rawad ; Hartshorn, Kevan ; Rahma, Osama ; Lin, Nina ; Snyder-Cappione, Jennifer E.</creatorcontrib><description>The advent of immune checkpoint inhibitors (ICIs) has changed the landscape of cancer treatment. Older adults represent the majority of cancer patients; however, direct data evaluating ICIs in this patient population is lacking. Aging is associated with changes in the immune system known as “immunosenescence” that could impact the efficacy and safety profile of ICIs. In this paper, we review aging-associated changes in the immune system as they may relate to cancer and immunotherapy, with mention of the effect of chronic viral infections and frailty. Furthermore, we summarize the current clinical evidence of ICI effectiveness and toxicity among older adults with cancer.</description><identifier>ISSN: 0093-7754</identifier><identifier>EISSN: 1532-8708</identifier><identifier>DOI: 10.1053/j.seminoncol.2018.08.006</identifier><identifier>PMID: 30539714</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Checkpoint inhibitors ; Frailty ; Immune senescence ; Immunotherapy ; Older adults</subject><ispartof>Seminars in oncology, 2018-08, Vol.45 (4), p.187-200</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-baf66e5c384bd65685718be04ca9d6b4b5f555a0e286d494cd567bfb94b8802c3</citedby><cites>FETCH-LOGICAL-c374t-baf66e5c384bd65685718be04ca9d6b4b5f555a0e286d494cd567bfb94b8802c3</cites><orcidid>0000-0001-7686-8998</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.seminoncol.2018.08.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30539714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elias, Rawad</creatorcontrib><creatorcontrib>Hartshorn, Kevan</creatorcontrib><creatorcontrib>Rahma, Osama</creatorcontrib><creatorcontrib>Lin, Nina</creatorcontrib><creatorcontrib>Snyder-Cappione, Jennifer E.</creatorcontrib><title>Aging, immune senescence, and immunotherapy: A comprehensive review</title><title>Seminars in oncology</title><addtitle>Semin Oncol</addtitle><description>The advent of immune checkpoint inhibitors (ICIs) has changed the landscape of cancer treatment. Older adults represent the majority of cancer patients; however, direct data evaluating ICIs in this patient population is lacking. Aging is associated with changes in the immune system known as “immunosenescence” that could impact the efficacy and safety profile of ICIs. In this paper, we review aging-associated changes in the immune system as they may relate to cancer and immunotherapy, with mention of the effect of chronic viral infections and frailty. Furthermore, we summarize the current clinical evidence of ICI effectiveness and toxicity among older adults with cancer.</description><subject>Checkpoint inhibitors</subject><subject>Frailty</subject><subject>Immune senescence</subject><subject>Immunotherapy</subject><subject>Older adults</subject><issn>0093-7754</issn><issn>1532-8708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkM9OwzAMxiMEgjF4BdQjBzqcNklTbmPinzSJC5yjJnVHpjUdyTa0G2_EO_EkZGzAEcmSJfuzP_tHSEJhQIHnl9NBwNa6zpluNsiAygHEALFHepTnWSoLkPukB1DmaVFwdkSOQ5gCZLTIskNylMclZUFZjzwMJ9ZNLj7fP2zbLh0mAR0Gg87gpli5OvludIsX9NV8fRWLw8R07dzjC7pgV5h4XFl8OyEHTTULeLrLffJ8e_M0uk_Hj3cPo-E4NXnBFqmuGiGQm1wyXQsuJC-o1AjMVGUtNNO84ZxXgJkUNSuZqbkodKNLpqWEzOR9cr7dO_fd6xLDQrU2HjybVQ67ZVAZ5ZwKEJxHqdxKje9C8Nioubdt5deKgtqAVFP1B1JtQCqIASKOnu1clrrF-nfwh1wUXG8FGH-N_3sVjN1gq61Hs1B1Z_93-QKXBo2a</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Elias, Rawad</creator><creator>Hartshorn, Kevan</creator><creator>Rahma, Osama</creator><creator>Lin, Nina</creator><creator>Snyder-Cappione, Jennifer E.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7686-8998</orcidid></search><sort><creationdate>201808</creationdate><title>Aging, immune senescence, and immunotherapy: A comprehensive review</title><author>Elias, Rawad ; Hartshorn, Kevan ; Rahma, Osama ; Lin, Nina ; Snyder-Cappione, Jennifer E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-baf66e5c384bd65685718be04ca9d6b4b5f555a0e286d494cd567bfb94b8802c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Checkpoint inhibitors</topic><topic>Frailty</topic><topic>Immune senescence</topic><topic>Immunotherapy</topic><topic>Older adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elias, Rawad</creatorcontrib><creatorcontrib>Hartshorn, Kevan</creatorcontrib><creatorcontrib>Rahma, Osama</creatorcontrib><creatorcontrib>Lin, Nina</creatorcontrib><creatorcontrib>Snyder-Cappione, Jennifer E.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elias, Rawad</au><au>Hartshorn, Kevan</au><au>Rahma, Osama</au><au>Lin, Nina</au><au>Snyder-Cappione, Jennifer E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aging, immune senescence, and immunotherapy: A comprehensive review</atitle><jtitle>Seminars in oncology</jtitle><addtitle>Semin Oncol</addtitle><date>2018-08</date><risdate>2018</risdate><volume>45</volume><issue>4</issue><spage>187</spage><epage>200</epage><pages>187-200</pages><issn>0093-7754</issn><eissn>1532-8708</eissn><abstract>The advent of immune checkpoint inhibitors (ICIs) has changed the landscape of cancer treatment. Older adults represent the majority of cancer patients; however, direct data evaluating ICIs in this patient population is lacking. Aging is associated with changes in the immune system known as “immunosenescence” that could impact the efficacy and safety profile of ICIs. In this paper, we review aging-associated changes in the immune system as they may relate to cancer and immunotherapy, with mention of the effect of chronic viral infections and frailty. Furthermore, we summarize the current clinical evidence of ICI effectiveness and toxicity among older adults with cancer.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30539714</pmid><doi>10.1053/j.seminoncol.2018.08.006</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-7686-8998</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0093-7754 |
| ispartof | Seminars in oncology, 2018-08, Vol.45 (4), p.187-200 |
| issn | 0093-7754 1532-8708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2155160655 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Checkpoint inhibitors Frailty Immune senescence Immunotherapy Older adults |
| title | Aging, immune senescence, and immunotherapy: A comprehensive review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A12%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aging,%E2%80%AFimmune%20senescence,%E2%80%AFand%20immunotherapy:%E2%80%AFA%20comprehensive%20review&rft.jtitle=Seminars%20in%20oncology&rft.au=Elias,%20Rawad&rft.date=2018-08&rft.volume=45&rft.issue=4&rft.spage=187&rft.epage=200&rft.pages=187-200&rft.issn=0093-7754&rft.eissn=1532-8708&rft_id=info:doi/10.1053/j.seminoncol.2018.08.006&rft_dat=%3Cproquest_cross%3E2155160655%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2155160655&rft_id=info:pmid/30539714&rft_els_id=S0093775418300034&rfr_iscdi=true |